ClinicalTrials.gg
TerminatedNCT05063786ALPHABETUpdated Oct 15, 2026

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)

A Phase 3 interventional study of Trastuzumab and Alpelisib in Advanced Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Terminated at 106 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Spanish Breast Cancer Research Group · Phase 3, Interventional, and Treatment

How we know · 13 judgments

Why this study was terminated
Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.
Updated Oct 15, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
26th of 38
27 · median 44
Started
2021
with 4 others
Phase 3
5 of 38
none open now
Registered
28th of 38
by date

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, and was the 28th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.

Read the detailed description

This is an international, multicenter, open-label, controlled phase III randomized clinical trial in HER2+ advanced breast cancer (ABC) patients harboring PIK3CA mutation.

Approximately 300 patients (144 in the Hormone Receptor (HR)- cohort and 156 in the HR+ cohort) will be enrolled.

Central screening of PIK3CA mutations on the most recent available formalin-fixed paraffinembedded (FFPE) tumor sample is required for the purpose of eligibility. Investigators will be encouraged to send the most recent tumor tissue, preferably from a metastatic lesion. However, if this is not possible, archived tissue samples either from primary tumor or metastatic lesion will be acceptable. Local screening of HR and HER2 status is required (although there will be a central confirmation done retrospectively).

Once the screening process (locally at each site and at the central laboratory) is completed, fully eligible patients will be randomized in a 1:1 fashion to the control arm with trastuzumab plus chemotherapy (CT) or to the experimental arm with trastuzumab + alpelisib +/- fulvestrant (depending on HR status). The two patient cohorts defined according to HR status will be randomized separately, with randomization in each cohort stratified by prior treatment with pertuzumab (yes vs no) and number of prior anti-HER2 based therapy lines for MBC (≤2 vs >2).

In both cohorts patients will continue to receive their assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.

After objective disease progression, patients in both treatment arms will be followed until death or withdrawal of consent.

In order to perform exploratory biomarker analysis, pre-treatment tumor and sequential blood samples (at baseline, at week 9, at the end of treatment (EOT), and at progressive disease (PD)) will be obtained. Additionally, blood samples from approximately 100 patients (50 HR+ and 50 HR-) screened and without PIK3CA mutation will be collected.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Alpelisib
  • Metastatic Breast Cancer
  • PIK3CA mutated
  • HER2 positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be enrolled for randomization in the study only if they meet all of the following criteria:

  1. Written prior to any specific study procedures, showing patient willingness to comply with all study procedures.
  2. or cytologically documented locally recurrent inoperable or breast cancer with + status based on local laboratory determination, preferably on the most recent available FFPE tumor sample, and according to American Society of ClinicalOncology (ASCO)/College of American Pathologists (CAP) international guidelines valid at the time of the assay. In case of discordance in HER2+ status in different , we will consider the result from the most recent biopsy one will be used.
  3. Documented HR status based on local laboratory, preferably on the most recent available FFPE tumor sample, and according to ASCO/CAP international guidelines valid at the time of the assay. In case of discordance in HR status in different biopsies, the result from the most recent biopsy will be used. HR+ will be defined as ≥1% positive cells by immunohistochemistry for Estrogen Receptor (ER) and/or Progesterone Receptor (PgR). HR- will be defined as \<1% positive cells by immunohistochemistry for both ER and PgR. Considering that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive, for the purpose of this study, patients with ER and PgR expression between 1 and 10% (considered to be HR low by the most recent ASCO/CAP guidelines) will be eligible for inclusion in the HR- cohort.
  4. Patients with a PIK3CA tumor mutation at central laboratory determination, preferably on the most recent available FFPE tumor sample.
  5. At least 1 but no more than 5 prior lines of anti-HER2 based therapy for metastatic breast cancer (MBC). Maintenance therapy will not count as an additional .
  6. At least 1 prior line of trastuzumab in the metastatic setting, or in the (neo) setting (provided the patient while on therapy or within 6 months after completing adjuvant trastuzumab).
  7. Female or male patient is at least 18 years of age.
  8. (ECOG) Performance Status 0-1.
  9. Patients can be either males or premenopausal/perimenopausal or females. In the HR+ cohort, males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 28 days prior to starting study treatment.

    Premenopausal status is defined as either:

    • Last menstrual period occurred within the last 12 months, or
    • If on tamoxifen: last menstrual period occurred within the past 14 days, plasma estradiol is ≥ 10 pg/mL and follicle-stimulating hormone (FSH) ≤ 40 IU/l or in the premenopausal range, according to local laboratory definition, or
    • In case of therapy induced amenorrhea: plasma estradiol is ≥ 10 pg/mL and FSH ≤ 40 IU/l or in the premenopausal range, according to local laboratory definition.

    Postmenopausal status is defined as either:

    - Natural (spontaneous) amenorrhea lasting more than 12 months and either age from49 to 59 years and/or history of vasomotor symptoms (e.g., hot flush) in the absence of other medical justification, or Levels of plasma estradiol ≤ 20 pg/mL and follicle-stimulating hormone (FSH) ≥ 40 IU/l or in the postmenopausal range, according to local laboratory definition, or Surgical bilateral oophorectomy.

    Perimenopausal status is defined as neither premenopausal nor postmenopausal.

  10. or at least one evaluable bone lesion, lytic or mixed (lytic+blastic), which has not been previously irradiated and is assessable by computer tomography (CT)/magnetic resonance imaging (MRI) in the absence of measurable disease according to 1.1 criteria.
  11. ≥ 12 weeks.
  12. Adequate organ and marrow function defined as follows:

    • (ANC) ≥ 1,500/mm3 (1.5x109/L).
    • ≥ 100,000/mm3 (100x109/L).
    • ≥ 9g/dL (90g/L).
    • Calcium (corrected for serum albumin) and magnesium within normal limits or ≤ grade 1 according to version 5.0 if judged clinically not significant by the investigator.
    • Creatinine \<1.5 x (ULN) or ≥ 35 mL/min using Cockcroft-Gault formula (if creatinine is ≥1.5 ULN).
    • Total \< 2 x ULN (any elevated bilirubin should be asymptomatic at enrollment) except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN.
    • Potassium within normal limits, or corrected with supplements.
    • (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN.

    If patient has liver metastasis, AST and ALT ≤ 5.0 x ULN (elevated AST or AST values must be stable for 2 weeks, without evidence of biliary obstruction by imaging).

    • Fasting serum amylase ≤ 2.0 x ULN.
    • Fasting serum lipase ≤ ULN.
    • Fasting plasma glucose (FPG) \< 140 mg/dL (7.7 mmol/L) and glycosylated hemoglobin () \< 6.5%.
  13. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI-CTCAE version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator´s discretion).
  14. Adequate cardiac function as defined by (LVEF) of ≥ 50% measured by echocardiography or multi-gated acquisition (MUGA) scans.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Have received more than 5 previous lines of anti- based therapy for MBC, or prior fulvestrant.
  2. Symptomatic visceral disease or any disease burden that makes the patient ineligible for experimental therapy per the investigator's best judgment.
  3. Symptomatic central nervous system (CNS) . However, patients with who have been adequately treated, are asymptomatic and do not require or anti-epileptic medication are eligible.
  4. Presence of .
  5. Other invasive (different from the current breast cancer) at the time of enrollment or previous diagnosis of a completely removed malignancy within 3 years prior to randomization except for adequately treated (including complete surgical removal) of International Federation of Gynecology and Obstetrics (FIGO) stage I grade 1 endometrial cancer, basal or squamous cell carcinoma of the skin, thyroid cancer limited to thyroid gland, in situ carcinoma of the cervix, and grade 1-2 early stage bladder cancer defined as T1 or less, without nodal involvement (N0).
  6. Patients with an established diagnosis of diabetes mellitus type I or not controlled type II (FPG ≥ 140 mg/dL [7.7 mmol/L] or ≥ 6.5%), or history of gestational diabetes (as per American College of Obstetricians and Gynecologists (ACOG) guidelines) or documented steroid-induced diabetes mellitus.
  7. Prior treatment with any mTOR, AKT or PI3K inhibitor.
  8. Patients treated within the last 7 days prior to treatment initiation with:

    • Drugs that are strong inducers of .
    • Drugs that are inhibitors of Breast Cancer Resistance Protein (BCRP).
  9. Patients who received before randomization:

    • Any agent within 4 weeks.
    • Chemotherapy within a period of time that is shorter than the cycle duration used for that treatment (e.g. \< 3 weeks for fluorouracil, doxorubicine, epirubicin or \< 1 week for weekly chemotherapy).
    • Biologic therapy (e.g., antibodies, other than trastuzumab which is permitted): within 4 weeks prior to starting study treatment.
    • Endocrine therapy: tamoxifen or aromatase inhibitor (AI) within 2 weeks prior to starting study treatment.
    • Corticosteroids within 2 weeks prior to starting study treatment. Note: the following uses of corticosteroids are permitted at any time: single doses, topical applications(e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).
    • Radiotherapy within 2 weeks prior to starting study treatment (all acute toxic effects must be resolved to version 5.0 grade \<1, except toxicities not considered a safety risk for the patient at investigator´s discretion). Patients who received prior radiotherapy to >25% of bone marrow are not eligible regardless of when it was administered.
    • Major surgery or other anti-cancer therapy not previously specified within 4 weeks prior to starting study treatment, (all acute toxic effects, including peripheral neurotoxicity must be resolved to NCI-CTCAE version 5.0 grade ≤ 1, except toxicities not considered a safety risk for the patient at the investigator´s discretion).
  10. Patient has , uncontrolled heart disease and/or recent cardiac events including any of the following:

    • History of angina pectoris, coronary artery bypass graft (CABG), symptomatic pericarditis or myocardial infarction within 6 months of randomization.
    • History of documented congestive heart failure ( functional classification III-IV).
    • Clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g. bifascicular block, Mobitz type II and third degree AV block without pacemaker in place).
    • Uncontrolled hypertension defined by a Systolic Blood Pressure ≥ 160 mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening.
    • Long syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or Fridericia QT correction formula (QTcF) > 470msec.
    • Bradycardia (heart rate \< 50 at rest), by (ECG) or pulse.
    • Inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF > 460 msec for females (using Fridericia's correction). All as determined by screening ECG.
  11. Bleeding diathesis (i.e., Disseminated Intravascular Coagulation (DIC), clotting factor deficiency) or long-term (> 6 months) anticoagulant therapy, other than antiplatelet therapy and low dose coumarin derivatives, provided that the (INR) is less than 1.5.
  12. History of clinically significant bowel disease including abdominal fistula, or gastrointestinal perforation.
  13. Difficulties to swallow tablets, malabsorption syndrome disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, or active inflammatory bowel disease (e.g., ulcerative diseases).
  14. Known to trastuzumab, alpelisib or fulvestrant or any of their . If known hypersensitivity to either vinorelbine, capecitabine, eribulin or any of their excipients, patient will be eligible as long as the investigator's choice avoids that drug in the control arm.

    If known hypersensitivity to all three cytostatics (vinorelbine, capecitabine and eribulin), the patient will not be eligible.

  15. Known positive serology for (HIV), or active infection for or .
  16. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  17. Patients with currently documented pneumonitis/interstitial lung disease (the chest Computed Tomography [CT] scan performed at screening for the purpose of tumor assessment should be reviewed to confirm that there are no relevant pulmonary complications present).
  18. Patient with liver disease with a score B or C.
  19. Patient with a history of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis.
  20. Patient has a history of Steven-Johnson-Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
  21. Patient is nursing (lactating) or is pregnant as confirmed by a positive serum human Chorionic Gonadotropin (hCG) test prior to initiating study treatment.
  22. Patient is a woman of or a partner of a woman of child-bearing potential, unless agreement to remain abstinent or use single or combined non-hormonal methods that result in a failure rate of \< 1% per year during the treatment period and for at least 7 months after the last dose of study treatment, except for patients receiving fulvestrant in which this period should be of at least 2 years.

    • Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient.
    • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include tubal ligation, male sterilization (only if he is the sole partner and have been performed at least 6 months prior to screening), and certain intrauterine devices.
    • Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \< 1% per year. Barrier methods must always be supplemented with the use of a spermicide.
    • Male participants must not donate sperm during study and up to the time period specified above.
Terms in these criteria, in plain language(42)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Experimental Arm (Arm A) Cohort 1 (HER2+/HR-)

    Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks. Alpelisib 300 mg oral once daily. \*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

    Biological: Trastuzumab · Drug: Alpelisib

  • Experimental
    Experimental Arm (Arm A) Cohort 2 (HER2+/HR+)

    Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks. Alpelisib 300 mg oral once daily. Fulvestrant 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1. Males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 28 days prior to starting study treatment, and should continue with this therapy. \*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

    Biological: Trastuzumab · Drug: Alpelisib · Drug: Fulvestrant

  • Active comparator
    Control Arm (Arm B ) Cohorts 1 and 2

    Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks. Chemotherapy (CT): vinorelbine, capecitabine or eribulin (according to investigator preference): * Vinorelbine either oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks. * Capecitabine: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks. * Eribulin: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks. * If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

    Biological: Trastuzumab · Drug: Vinorelbine · Drug: Capecitabine · Drug: Eribulin

Interventions

  • BiologicalTrastuzumab

    6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks. \* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

    Also known as: Herceptin

  • 300 mg oral once daily.

    Also known as: Piqray

  • 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.

    Also known as: Faslodex

  • Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.

    Also known as: Navelbine

  • 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.

    Also known as: Xeloda

  • 1.23 mg/m2 IV on days 1 and 8, every 3 weeks.

    Also known as: Halaven

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time from randomization to objective disease progression based on the investigator's assessment according to the response evaluation criteria for solid tumors (RECIST) version 1.1., or death from any cause.

    Time frame: The accumulation of targeted PFS events is estimated at 44 and 38 months since first patients randomized, in the HR- and HR+ cohorts, respectively.

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to death from any cause.

    Time frame: Approximately 59 months from the inclusion of the first patient.

  2. Objective Response (OR)

    Complete or partial response as best overall response based on the investigator's assessment according to RECIST version 1.1.

    Time frame: Through study completion, an average of 59 months from the inclusion of the first patient.

  3. Safety and tolerability

    Adverse events (AEs) grades will be defined by the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. AE terms will be coded according to the MedDRA dictionary.

    Time frame: During the study treatment period or within 30 days of the last dose of study treatment.

Other outcomes

  1. Time to first subsequent therapy (TFST)

    Time from randomization to the initiation of the first subsequent line of systemic therapy after the study therapy or death from any cause.

    Time frame: After disease progression or unacceptable toxicity up approximately 59 months from the inclusion of the first patient.

  2. Time to first subsequent therapy cessation (TFSTC)

    Time from randomization to the cessation of the first subsequent line of systemic therapy for any reason (i.e., progression, toxicity, death from any cause, etc.).

    Time frame: At the finalization of the first subsequent line of systemic therapy after study treatment estimated to be approximately 59 months from the inclusion of the first patient.

  3. Change in the National Comprehensive Cancer Network - Functional- Breast Cancer Symptom Index-16 (NFBSI) summary score from baseline to 9 weeks after randomization

    NFBSI-16 is a 16-item assessment of disease-related symptoms, treatment side effects, and general function and well-being. The instrument has 3 subscales: disease-related symptoms (DRS) - 9 items; treatment side-effects (TSE) - 4 items; and general function and well-being (F/WB) - 3 items. All items have a 7-day recall period and a 5-point verbal descriptive response scale ranging from 0 ("not at all") to 4 ("very much"). NFBSI-16 summary scores range from 0-64, with higher scores indicating less symptomatology and better QoL. Scoring of summary and subscale scores will be based on the FACIT.org scoring guidelines. Patients must complete each paper-based QoL questionnaire during their visits in the clinic and prior to having any tests and to any discussion of their health status with healthcare personnel at the site. A longitudinal assessment will be used to assess differential effects of the randomized treatments on patients' QoL

    Time frame: Baseline and 9 weeks after randomization.

  4. Time to deterioration (TTD) in QoL.

    Time from randomization to the first time the patient's NFBSI-16 summary score shows a ≥ 4 points decrease from baseline for at least two consecutive assessments, or an initial score decrease of ≥ 4 points followed by death before the next assessment timepoint.

    Time frame: QoL will be assessed at baseline;every 3 weeks until week 9 and then every 6 weeks until progression and at the post-treatment visit.

  5. PIK3CA mutations determined in tumor and blood samples, and their correlation with efficacy variables.

    Time frame: At baseline, at week 9, at the end of treatment [EOT] and at Progression Disease estimated up to 9 months.

07

Study locations

106 sites
  • Medizinische Universität Innsbruck - Univ.Klinik f. Frauenheilkunde Innsbruck
    Innsbruck, Austria
  • LKH Hochsteiermark - Leoben
    Leoben, Austria
  • Ordensklinikum Linz GmbH - BHS
    Linz, Austria
  • Universitätsklinikum St. Pölten
    Pölten, Austria
  • Pyhrn - Eisenwurzen Klinikum Steyr
    Steyr, Austria
  • Klinik Hietzing Wien
    Vienna, Austria
  • Klinik Ottakring
    Vienna, Austria
  • Medizinische Universität Wien - Univ.klinikum AKH Wien
    Vienna, Austria
  • Centre d'Oncologie et Radiothérapie 37
    Chambray-lès-Tours, France
  • Centre Jean Perrin
    Clermont-Ferrand, France
  • Centre Régional De Lutte Contre Le Cancer Georges-François Leclerc
    Dijon, France
  • Centre hospitalier universitaire à Limoges
    Limoges, France
  • Institut Curie Hospital
    Paris, France
  • Centre hospitalier universitaire de Poitiers
    Poitiers, France
  • Institute Curie - Site Saint-Cloud
    Saint-Cloud, 92210, France
  • A.O. "SS Antonio e Biagio e Cesare Arrigo"
    Alessandria, Italy
  • Clinica Oncologica, AOU Riuniti
    Ancona, Italy
  • Ospedale di Bolzano Azienda Sanitaria Alto Adige
    Bolzano, Italy
  • Ospedale MultiMedica Castellanza
    Castellanza, Italy
  • Cannizzaro Hospital
    Catania, Italy
  • ASST Cremona
    Cremona, Italy
  • Azienda Ospedaliero-Universitaria Careggi, University of Florence
    Florence, Italy
  • IRCCS Policlinico San Martino
    Genoa, Italy
  • Mater Salutis Hospital
    Legnago, Italy
  • ASST-Mantova- Hospital Carlo Poma
    Mantua, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei tumori
    Meldola, Italy
  • IRCCS Ospedale San Raffaele
    Milan, Italy
  • IEO - Istituto Europeo di Oncologia
    Milan, Italy
  • Ospedali Riuniti Monselice Padova
    Monselice, Italy
  • AOU Maggiore della Caritá
    Novara, Italy
  • Casa di Cura La Maddalena S.P.A.
    Palermo, Italy
  • Azienda Ospedaliero-Universitaria di Parma
    Parma, Italy
  • Istituti Clinici Scientifici Maugeri SpA-SB
    Pavia, Italy
  • AUSL Romagna/Oncology Department
    Rimini, Italy
  • Istituti Fisioterapici ospitaliersi - IFO - Istituti Regina Elena
    Roma, Italy
  • Policlinico Umberto I
    Roma, Italy
  • UOSD AUSL Modena
    Sassuolo, Italy
  • Santa Chiara Hospital
    Trento, Italy
  • Sant'Anna Hospital - Città della salute e della scienza
    Turin, Italy
  • Department of Oncology, ASUFC, PO Sm Misericordia
    Udine, Italy
  • Radboud Medical Center
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Meander Medisch Centrum
    Amersfoort, Netherlands
  • Adrz Medisch Centrum
    Goes, Netherlands
  • Martini Ziekenhuis
    Groningen, Netherlands
  • Maastricht UMC
    Maastricht, Netherlands
  • ZorgSaam Ziekenhuis
    Terneuzen, Netherlands
  • HagaZiekenhuis
    The Hague, Netherlands
  • Diakonessenhuis Utrecht
    Utrecht, Netherlands
  • VieCuri Medisch Centrum
    Venlo, Netherlands
  • Centro Oncoloxico de Galicia
    A Coruña, Spain
  • Complexo Hospitalario Universitario A Coruña
    A Coruña, Spain
  • Hospital Clínico Universitario de Santiago CHUS
    A Coruña, Spain
  • Complejo Hospitalario Universitario de Albacete
    Albacete, Spain
  • Hospital General Universitario de Alicante
    Alicante, Spain
  • Hospital Universitario de Badajoz
    Badajoz, Spain
  • ICO Badalona - Hospital Universitario Germans Trias i Pujol
    Badalona, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitario Basurto
    Bilbao, 48013, Spain
  • Hospital Galdakao-Usansolo
    Bilbao, Spain
  • Hospital Universitario de Cruces
    Bilbao, Spain
  • Hospital Universitario Puerta del Mar
    Cadiz, Spain
  • Hospital San Pedro de Alcántara
    Cáceres, Spain
  • Hospital Universitario Donostia
    Donostia / San Sebastian, Spain
  • Hospital General Universitario de Elche
    Elche, Spain
  • ICO de Girona - Hospital Josep Trueta
    Girona, Spain
  • Hospital Universitario Clínico San Cecilio
    Granada, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, Spain
  • Hospital Universitario Juan Ramón Jiménez
    Huelva, Spain
  • Hospital Universitario de Jaen
    Jaén, Spain
  • Hospital Universitario de Jerez de la Frontera
    Jerez de la Frontera, Spain
  • Hospital Universitario Arnau de Vilanova de Lleida
    Lleida, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Spain
  • Hospital Universitario de Fuenlabrada
    Madrid, Spain
  • Hospital Universitario HM Sanchinarro - CIOCC Clara Campal
    Madrid, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, Spain
  • Hospital Universitario Severo Ochoa
    Madrid, Spain
  • Althaia Xarxa Assistencial de Manresa
    Manresa, Spain
  • Hospital de Mataró
    Mataró, Spain
  • Hospital Universitario Regional de Malaga
    Málaga, Spain
  • Hospital Clinico Universitario Virgen de La Arrixaca
    Murcia, Spain
  • Hospital Universitario Son Espases
    Palma de Mallorca, Spain
  • Hospital Universitario Son Llatzer
    Palma de Mallorca, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, Spain
  • Corporació Sanitaria Parc Taulí
    Sabadell, Spain
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Spain
  • Hospital Universitario Nuestra Señora de la Candelaria
    Santa Cruz de Tenerife, Spain
  • Hospital Universitario Virgen de Valme
    Seville, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
  • Hospital Universitario Sant Joan de Reus
    Tarragona, Spain
  • Hospital de Terrassa - Consorci Sanitari de Terrassa
    Terrassa, Spain
  • Hospital Virgen de la Salud
    Toledo, Spain
  • Consorcio Hospital General Universitario de Valencia
    Valencia, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, Spain

Showing the first 100 of 106 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Perez-Fidalgo JA, Criscitiello C, Carrasco E, Regan MM, Di Leo A, Ribi K, Adam V, Bedard PL. A phase III trial of alpelisib + trastuzumab +/- fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer. Future Oncol. 2022 Jun;18(19):2339-2349. doi: 10.2217/fon-2022-0045. Epub 2022 Apr 25. PubMed 35465733 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2021 to primary completion in Dec 2025, 51 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2026 → Dec 2025 and completion Jun 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2021
First posted
Oct 1, 2021
StartActual
Sep 14, 2021
Primary completionActual
Dec 23, 2025was Jun 2026
CompletionActual
Dec 23, 2025was Jun 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.
changed Oct 15, 2026
Primary completion
Jun 2026→Dec 23, 2025 (actual)
Oct 15, 2026
Study completion
Jun 2026→Dec 23, 2025 (actual)
Oct 15, 2026
Title
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated-mutated HER2+ Advanced BrEasT CancerBC (ALPHABET)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Terminated
    Why stopped Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.
    Primary completion Jun 2026→Dec 23, 2025 (now actual)
    Study completion Jun 2026→Dec 23, 2025 (now actual)
    Title Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated-mutated HER2+ Advanced BrEasT CancerBC (ALPHABET)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05063786
Lead sponsor
Spanish Breast Cancer Research Group
Collaborators
ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Sep 14, 2021
Primary completion
Dec 23, 2025
Completion
Dec 23, 2025
Last update
Oct 15, 2026

Study contacts

Study Director
study director · H. Clínico Universitario Valencia. Valencia, Spain.
Study Director
study director · Istituto Europeo di Oncologia. Milan, Italy.
Study Director
study director · Princess Margaret Cancer Center. Toronto, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Fulvestrant

Start the discussion